PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma
Although the overall survival was improved with the introduction of high dose therapy with
autologous hematopoetic stem cell transplantation,it remains as a incurable disease. Most
patients ultimately relapse. Recenlty, targeted therapy using novel agents, such as
bortezomib and thalidomide, shows the possibility of improved in this situation. Among them,
PAD (Velcade, Adriamycin,Dexamethasone) showed highest response rate. PAD does not show any
cross resiatance with another effective combination, thalidomide plus dexamethasone.
We desined prospective multicenter phase 2 study using these combination sequentially.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate of PAD induction Therapy
Jae Hoon Lee, M.D.
Korean Multiple Myeloma Working Party
South Korea: Korea Food and Drug Administration (KFDA)